MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
32.4 M |
Market Cap[1] |
$ 728 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Eiger BioPharmaceuticals
EIGR
|
- | -9.21 % | $ 2.55 M | Nasdaq Global Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
BELLUS Health
BLU
|
- | - | $ 2.47 B | Nasdaq Global Select Market |  Canada |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Intra-Cellular Therapies
ITCI
|
- | - | $ 13.6 B | Nasdaq Global Select Market,SPB | USA |
 |
IGM Biosciences
IGMS
|
- | - | $ 76.9 M | Nasdaq Global Select Market,SPB | USA |
 |
Marinus Pharmaceuticals
MRNS
|
- | - | $ 29.6 M | Nasdaq Global Select Market | USA |
 |
Merrimack Pharmaceuticals
MACK
|
- | - | $ 216 M | Nasdaq Global Market | USA |
 |
CASI Pharmaceuticals
CASI
|
- | - | $ 35.4 M | Nasdaq Capital Market | USA |
 |
ContraFect Corporation
CFRX
|
- | -5.16 % | $ 5.39 M | Nasdaq Capital Market | USA |
 |
Rubius Therapeutics
RUBY
|
- | -33.55 % | $ 7.81 M | Nasdaq Global Select Market | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
TRACON Pharmaceuticals
TCON
|
- | -1.38 % | $ 46.8 M | Nasdaq Capital Market | USA |
 |
Mirati Therapeutics
MRTX
|
- | - | $ 3.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Revance Therapeutics
RVNC
|
- | - | $ 309 M | Nasdaq Global Select Market | USA |
 |
Allogene Therapeutics
ALLO
|
$ 0.93 | -11.99 % | $ 205 M | Nasdaq Global Select Market,SPB | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
- | -37.48 % | $ 476 K | Nasdaq Capital Market | USA |
 |
Epizyme
EPZM
|
- | - | $ 249 M | Nasdaq Global Select Market | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
ORIC Pharmaceuticals
ORIC
|
$ 8.9 | -3.63 % | $ 781 M | Nasdaq Global Select Market | USA |
 |
Forward Pharma A/S
FWP
|
- | -0.75 % | $ 18.7 M | Nasdaq Capital Market |  Danmark |
 |
Orchard Therapeutics plc
ORTX
|
- | 1.02 % | $ 90.8 M | Nasdaq Global Select Market |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
- | - | $ 154 M | Nasdaq Capital Market | USA |
 |
Oyster Point Pharma
OYST
|
- | - | $ 300 M | Nasdaq Global Select Market | USA |
 |
Nabriva Therapeutics plc
NBRV
|
- | - | $ 4.55 M | Nasdaq Global Select Market |  Irlanda |
 |
Intercept Pharmaceuticals
ICPT
|
- | - | $ 643 M | Nasdaq Global Select Market,SPB | USA |
 |
NGM Biopharmaceuticals
NGM
|
- | - | $ 127 M | Nasdaq Global Select Market,SPB | USA |
 |
Regulus Therapeutics
RGLS
|
- | - | $ 155 M | Nasdaq Global Select Market | USA |
 |
9 Meters Biopharma
NMTR
|
- | -42.97 % | $ 1.05 M | Nasdaq Global Select Market | USA |
 |
Chinook Therapeutics
KDNY
|
- | - | $ 2.6 B | Nasdaq Global Select Market | USA |
 |
Lumos Pharma
LUMO
|
- | - | $ 35.3 M | Nasdaq Global Select Market | USA |
 |
Syros Pharmaceuticals
SYRS
|
- | -8.44 % | $ 3.4 M | Nasdaq Global Select Market | USA |
 |
NanoViricides
NNVC
|
$ 1.44 | 8.27 % | $ 29.1 M | NYSE American | USA |
 |
Gamida Cell Ltd.
GMDA
|
- | -18.25 % | $ 5.04 M | Nasdaq Global Market |  Israel |
 |
GT Biopharma
GTBP
|
$ 3.99 | -7.64 % | $ 22 M | Nasdaq Capital Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 1.52 | -3.8 % | $ 3.75 B | Nasdaq Capital Market | Israel |
 |
VistaGen Therapeutics
VTGN
|
$ 0.18 | -0.46 % | $ 6.85 M | Nasdaq Global Select Market | USA |
 |
C4 Therapeutics
CCCC
|
$ 3.0 | -4.76 % | $ 249 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.67 | -0.6 % | $ 2.75 M | NYSE American | Israel |
 |
Cytokinetics, Incorporated
CYTK
|
$ 56.2 | 1.92 % | $ 6.75 M | Nasdaq Global Select Market,SPB | USA |
 |
Curis
CRIS
|
$ 0.66 | -5.68 % | $ 8.69 M | Nasdaq Global Market | USA |
 |
Exelixis
EXEL
|
$ 71.0 | -1.04 % | $ 19.3 B | Nasdaq Global Select Market,SPB | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Amgen
AMGN
|
$ 465.26 | 0.01 % | $ 250 B | Nasdaq Global Select Market,SPB | USA |
 |
Biogen
BIIB
|
$ 253.37 | -0.59 % | $ 37.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Edesa Biotech
EDSA
|
$ 2.01 | -19.28 % | $ 11.4 M | Nasdaq Capital Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 15.12 | -0.72 % | $ 978 M | NYSE | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.